MGO One Seven LLC Raises Position in Edwards Lifesciences Co. (NYSE:EW)

MGO One Seven LLC grew its position in Edwards Lifesciences Co. (NYSE:EW) by 16.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,658 shares of the medical research company’s stock after acquiring an additional 931 shares during the period. MGO One Seven LLC’s holdings in Edwards Lifesciences were worth $493,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in EW. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences during the fourth quarter worth about $26,000. Millstone Evans Group LLC acquired a new position in Edwards Lifesciences during the fourth quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $30,000. Roble Belko & Company Inc acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $46,000. Finally, Catalyst Capital Advisors LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $54,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 1.2 %

Shares of NYSE EW opened at $76.06 on Monday. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The firm has a market cap of $44.71 billion, a price-to-earnings ratio of 10.91, a PEG ratio of 4.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock’s 50-day simple moving average is $70.94 and its 200-day simple moving average is $71.11.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same period in the previous year, the company earned $0.66 earnings per share. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on EW shares. Barclays boosted their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. Robert W. Baird boosted their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a “neutral” rating in a research report on Thursday. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Truist Financial cut their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating for the company in a research report on Friday, April 11th. Finally, Evercore ISI dropped their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $79.45.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the transaction, the vice president now directly owns 22,588 shares in the company, valued at $1,569,414.24. The trade was a 1.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the transaction, the chief executive officer now owns 59,083 shares of the company’s stock, valued at approximately $4,106,859.33. The trade was a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,853 shares of company stock valued at $5,163,062 over the last three months. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.